Medicine:长期应用ACEI与结核病风险下降相关

2016-05-19 phylis 译 MedSci原创

大量的流行病学资料表明,使用血管紧张素转换酶抑制剂(ACEI)可改善肺炎的临床预后。结核病(TB)是一种空气中的细菌导致的肺部疾病,像是肺炎。研究者旨在探讨应用ACEI是否能够降低活动性肺结核的风险。研究者应用来自台湾全民健康保险研究资料库中的100万纵向随访队列,进行了一项巢式病例对照研究。应用条件Logistic回归估计TB的RR值,并采用涉及71个结核病相关协变量的结核病特定疾病风险评分(D

大量的流行病学资料表明,使用血管紧张素转换酶抑制剂(ACEI)可改善肺炎的临床预后。结核病(TB)是一种空气中的细菌导致的肺部疾病,像是肺炎。研究者旨在探讨应用ACEI是否能够降低活动性肺结核的风险。

研究者应用来自台湾全民健康保险研究资料库中的100万纵向随访队列,进行了一项巢式病例对照研究。应用条件Logistic回归估计TB的RR值,并采用涉及71个结核病相关协变量的结核病特定疾病风险评分(DRS)校正。

从1997年1月到2011年12月,共有75536例患者应用ACEI,并且识别了7720例新发活动性肺结核。目前使用(DRS 校正RR,0.87 ; 95% CI,0.78-0.97 ),而不是最近和过去使用的ACEI,与活动性肺结核的风险下降相关。有趣的是,研究发现,长期使用(超过90天)药物与结核病的风险进一步降低相关(aRR,0.74, 95% CI,0.66-0.83 )。这存在持续反应效应,TB风险下降与长期应用ACEI相关。各亚组患者(年龄、性别、心脏衰竭、脑血管疾病、心肌梗塞、肾疾病,糖尿病)及接受其他心血管药物的患者,TB风险下降是一致的。

在这项大型基于人群的研究中,研究者发现,受试者的近期及长期使用ACEI与结核病的风险下降相关。

原始出处:

Wu JY, Lee MT, et al. Angiotensin-Converting Enzyme Inhibitors and Active Tuberculosis: A Population-Based Study. Medicine (Baltimore). 2016 May.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1655737, encodeId=ee841655e3728, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Wed Mar 22 14:45:00 CST 2017, time=2017-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773547, encodeId=1c271e7354760, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Fri Jan 06 03:45:00 CST 2017, time=2017-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858675, encodeId=d82818586e5ff, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Dec 13 23:45:00 CST 2016, time=2016-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=130331, encodeId=387a13033108, content=不错哦继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 18 15:37:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253987, encodeId=a2cf125398e8e, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sat May 21 12:45:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577473, encodeId=8e6e15e747369, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat May 21 12:45:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606922, encodeId=edd51606922af, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat May 21 12:45:00 CST 2016, time=2016-05-21, status=1, ipAttribution=)]
    2017-03-22 shanyongle
  2. [GetPortalCommentsPageByObjectIdResponse(id=1655737, encodeId=ee841655e3728, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Wed Mar 22 14:45:00 CST 2017, time=2017-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773547, encodeId=1c271e7354760, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Fri Jan 06 03:45:00 CST 2017, time=2017-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858675, encodeId=d82818586e5ff, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Dec 13 23:45:00 CST 2016, time=2016-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=130331, encodeId=387a13033108, content=不错哦继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 18 15:37:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253987, encodeId=a2cf125398e8e, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sat May 21 12:45:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577473, encodeId=8e6e15e747369, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat May 21 12:45:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606922, encodeId=edd51606922af, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat May 21 12:45:00 CST 2016, time=2016-05-21, status=1, ipAttribution=)]
    2017-01-06 kalseyzl
  3. [GetPortalCommentsPageByObjectIdResponse(id=1655737, encodeId=ee841655e3728, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Wed Mar 22 14:45:00 CST 2017, time=2017-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773547, encodeId=1c271e7354760, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Fri Jan 06 03:45:00 CST 2017, time=2017-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858675, encodeId=d82818586e5ff, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Dec 13 23:45:00 CST 2016, time=2016-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=130331, encodeId=387a13033108, content=不错哦继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 18 15:37:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253987, encodeId=a2cf125398e8e, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sat May 21 12:45:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577473, encodeId=8e6e15e747369, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat May 21 12:45:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606922, encodeId=edd51606922af, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat May 21 12:45:00 CST 2016, time=2016-05-21, status=1, ipAttribution=)]
    2016-12-13 jeanqiuqiu
  4. [GetPortalCommentsPageByObjectIdResponse(id=1655737, encodeId=ee841655e3728, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Wed Mar 22 14:45:00 CST 2017, time=2017-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773547, encodeId=1c271e7354760, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Fri Jan 06 03:45:00 CST 2017, time=2017-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858675, encodeId=d82818586e5ff, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Dec 13 23:45:00 CST 2016, time=2016-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=130331, encodeId=387a13033108, content=不错哦继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 18 15:37:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253987, encodeId=a2cf125398e8e, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sat May 21 12:45:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577473, encodeId=8e6e15e747369, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat May 21 12:45:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606922, encodeId=edd51606922af, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat May 21 12:45:00 CST 2016, time=2016-05-21, status=1, ipAttribution=)]
    2016-09-18 1e10c84am36(暂无匿称)

    不错哦继续关注

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1655737, encodeId=ee841655e3728, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Wed Mar 22 14:45:00 CST 2017, time=2017-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773547, encodeId=1c271e7354760, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Fri Jan 06 03:45:00 CST 2017, time=2017-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858675, encodeId=d82818586e5ff, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Dec 13 23:45:00 CST 2016, time=2016-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=130331, encodeId=387a13033108, content=不错哦继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 18 15:37:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253987, encodeId=a2cf125398e8e, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sat May 21 12:45:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577473, encodeId=8e6e15e747369, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat May 21 12:45:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606922, encodeId=edd51606922af, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat May 21 12:45:00 CST 2016, time=2016-05-21, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1655737, encodeId=ee841655e3728, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Wed Mar 22 14:45:00 CST 2017, time=2017-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773547, encodeId=1c271e7354760, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Fri Jan 06 03:45:00 CST 2017, time=2017-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858675, encodeId=d82818586e5ff, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Dec 13 23:45:00 CST 2016, time=2016-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=130331, encodeId=387a13033108, content=不错哦继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 18 15:37:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253987, encodeId=a2cf125398e8e, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sat May 21 12:45:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577473, encodeId=8e6e15e747369, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat May 21 12:45:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606922, encodeId=edd51606922af, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat May 21 12:45:00 CST 2016, time=2016-05-21, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1655737, encodeId=ee841655e3728, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Wed Mar 22 14:45:00 CST 2017, time=2017-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773547, encodeId=1c271e7354760, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Fri Jan 06 03:45:00 CST 2017, time=2017-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858675, encodeId=d82818586e5ff, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Dec 13 23:45:00 CST 2016, time=2016-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=130331, encodeId=387a13033108, content=不错哦继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 18 15:37:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253987, encodeId=a2cf125398e8e, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sat May 21 12:45:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577473, encodeId=8e6e15e747369, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat May 21 12:45:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606922, encodeId=edd51606922af, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat May 21 12:45:00 CST 2016, time=2016-05-21, status=1, ipAttribution=)]

相关资讯

JACC:肾功不全的心肌梗死患者可应用ACEI/ARB治疗

背景:血管紧张素转换酶抑制剂(ACEI)和血管紧张素受体拮抗剂(ARB)是否应该用于急性心肌梗死(AMI)后所有患者或仅高危患者的二级预防尚有争议。目标:本研究旨在探讨AMI后,不同风险状况下(包括肾小球滤过率),ACEI/ARB治疗与良好预后的相关性。方法:瑞典的研究者评估了2006至2009期间,瑞典登记记录中AMI幸存者出院后和随访中应用ACEI/ARB的数据。应用Cox比例风险模型研究(意

EMA发布声明,两类RAS抑制剂不应联用

4月11日,欧洲药物管理局(EMA)发布声明提醒,建议不要同时应用2类作用于肾素-血管紧张素系统(RAS)的药物[包括血管紧张素受体拮抗剂(ARB)、血管紧张素转换酶抑制剂(ACEI)和直接肾素抑制剂],尤其是对糖尿病肾病患者不能同时应用ARB和ACEI。 EMA指出,联用多种RAS抑制剂的主要风险包括高血钾、低血压、肾功能恶化(与单用一种RAS抑制剂相比)等。 2013年

JAMA Neurol:ACEI可降肌萎缩侧索硬化症风险?

台湾一项研究表明,血管紧张素转化酶抑制剂(ACEI)应用与肌萎缩侧索硬化症(ALS)形成风险存在剂量依赖负相关性。论文于11月10在线发表于《美国医学会杂志·神经病学》。此项基于人群的病例对照研究共纳入729例新诊断ALS患者,以及14580例性别、年龄、居住地和保险与之相匹配的对照者。以累积限定日剂量(cDDD)代表药物应用持续时间评估ACEI应用与ALS形成风险之间的相关性。结果显示,

Medicine:老年患者选择ACEI或者ARB?

老年患者肾素和醛固酮的活性水平较低,这使得人们对使用血管紧张素转换酶抑制剂(ACEI)和血管紧张素II受体阻滞剂(ARB)的益处和风险比较关注。然而,直接比较老年人群应用ACEI 和ARB的效果的数据是不一致的。这项全国性研究是从台湾全民健康保险数据库中选取2000至2009的患者,并随访至2010年底,所有患者年龄均≥ 70岁。应用高维的倾向评分(hdPS)将ARB组(12347例患者连续使用A

ACEI或ARB可减少高血压患者阿尔兹海默病风险

最新研究结果显示,廉价的降血压治疗同时能保护患者的大脑免受阿尔兹海默病的困扰。与未接受降血压治疗的患者相比,那些服用血管紧张素转换酶抑制剂(ACEI)类或血管紧张素受体拮抗剂(ARB)类药物控制血压的患者罹患阿尔兹海默病的可能性更低。该研究报告同时发表于2015年老年痴呆症协会国际会议。 穿过血脑屏障是关键 已往研究证实,如果患者中年之前出现高血压,那之后该患者罹患阿尔兹海默症的可能性

JAMA Intern Med:糖尿病患者使用ACEI比ARB获益更多

近年来糖尿病发病率逐年上升,预计到2030年全球约有3.5亿糖尿病患者。糖尿病是心血管疾病(CVD)独立危险因素,也是早产儿死亡主导因素。全球每年约有6.8%成年人死于糖尿病导致的心脏病或卒中。 肾素-血管紧张素-醛固酮系统(RAAS)是心血管及肾脏功能的主要调节系统,大量临床试验表明抑制RAAS系统可以减少心血管死亡率和全因死亡率。但是,DIABHYCAR研究和ROADMAP研究使得RAAS抑